---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122244"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:39:52.727261+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q3 net loss $30.5M; ADI-001 trial expanded to six autoimmune indications

## Summary
- Net loss of $30.5M ($0.34 per share) vs $49.9M ($1.16) in Q3 2023; cash $202.1M.
- ADI-001 Phase 1 now covers LN, SLE, SSc, IIM, SPS, AAV; preliminary LN data expected 1H25.
- FDA cleared IND amendment for ADI-001 in IIM and SPS in October 2024.
- ADI-270 granted Fast Track for metastatic/advanced ccRCC; Phase 1 enrollment planned in Q4 2024.
- Appointed Lloyd Klickstein, M.D., Ph.D. to Board of Directors in August 2024.

## SEC filing metadata
- accession: 0000950170-24-122244
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024122244/0000950170-24-122244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024122244/acet-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122244
- JSON: https://secwatch.observer/filing/0000950170-24-122244.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.